SpringWorks Therapeutics, Inc.

As of March 31, 2025, SpringWorks Therapeutics, Inc. has 74.99M shares outstanding.

These figures are as of March 31, 2025. The price-to-sales ratio is 14.95, and the price-to-book ratio stands at -2.66.

These figures are as of March 31, 2025. The EV/Sales ratio of 13.67 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative.

As of March 31, 2025, SpringWorks Therapeutics, Inc. maintains a current ratio of 4.33, meaning it holds 4.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1.77, indicating elevated leverage, while an interest coverage ratio of -261.42 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended March 31, 2025. Return on assets (ROA) is negative at -43.70, reflecting losses generated across the asset base. Inventory turnover of 1.69 indicates how many times SpringWorks Therapeutics, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended March 31, 2025, SpringWorks Therapeutics, Inc. posted a gross margin of 93.23, reflecting its pricing power and cost economics. The operating margin of -120.52 and net profit margin of -115.60 provide insight into operational efficiency.

These figures cover the twelve months ended March 31, 2025. Free cash flow yield is negative at -4.88: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 0.16, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to SpringWorks Therapeutics, Inc. shareholders.

As of March 31, 2025, SpringWorks Therapeutics, Inc. has an Altman Z-Score of 18.33, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.